Today, Golden Helix and Fluxion Biosciences announced a collaboration in a value-added reseller relationship. The relationship will bring the VarSeq software application to Fluxion’s global client base providing them with a method to study tumor DNA in the circulation. Fluxion is proud to offer the capability as it helps move them toward their goal of offering a complete sample-to-answer workflow for NGS profiling of cancer from a blood sample.

Fluxion is a leader in the molecular profiling of tumor cells using a routine blood draw, having commercialized the IsoFlux System for routine sequencing of circulating tumor cells (CTCs) using targeted cancer panels. This partnership will leverage the VarSeq software in order to provide IsoFlux customers with clinical analytic capabilities.

Golden Helix sees the analysis of blood samples for cancer diagnosis as a key area to advancing precision medicine and we are excited to support Fluxion Biosciences and their clients.

The full press release can be read on our website here.